Strides Pharma hits 52-week low, slumps 9% on weak Q2 results
newsdepo.com
The management said a muted sales performance accompanied with a drop in gross margins and relatively higher operating costs has led to a negative operating leverage in H1Strides Pharma hits 52-week low, slumps 9% on weak Q2 results
The management said a muted sales performance accompanied with a drop in gross margins and relatively higher operating costs has led to a negative operating leverage in H1 Read more
